

# COVID-19 VACCINATION

## IN PEOPLE (12+ YEARS) WITH DOWN SYNDROME:

### THE TRISOMY 21 RESEARCH SOCIETY SURVEY




### Take home messages

In line with data from the general population, our survey of 1708 vaccinated individuals with Down syndrome shows that the COVID-19 vaccine is safe and effective for individuals with Down syndrome:

- Most people had either no or very mild reactions after vaccination
- Less than 1% of the vaccinated individuals with Down syndrome contracted COVID-19 after vaccination
- All individuals with Down syndrome who had COVID-19 after vaccination fully recovered

### 1895 participants age 12+ years

- 1708 (90.1%) have had at least 1 dose
- 1482 (86.7%) have had a second dose
- 187 (9.8%) have not received the vaccine
  - 36 (20%) because vaccine not available yet
  - 15 (9%) for medical reasons
  - 129 (70%) for other reasons



United States : 751

Brazil : 209

United Kingdom : 202

Canada : 123

Italy : 109

France : 91

India : 51

Spain : 35

Other : 127


### Study participants

| Vaccine manufacturer |                          |
|----------------------|--------------------------|
| 58.1%                | Pfizer-BioNTech          |
| 19.1%                | Moderna                  |
|                      | Oxford-                  |
| 19.5%                | AstraZeneca / Covishield |
| 1.3%                 | Johnson & Johnson        |
| 2%                   | Other                    |


## Results stratified by age

| Age 12 – 17 (n=329) | Age 18 + (n=1379) |
|---------------------|-------------------|
|---------------------|-------------------|

## Reactions similar to those reported by people without Down syndrome



## Very few reactions required clinical care



## 0.8% of vaccinated people contracted COVID-19 infections after vaccination

| 0.3% of those 12 – 17 years                                                                                                                                                                                                       | 0.9% of those 18+ years                                                                                                           |                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <u>1 case after 2<sup>nd</sup> dose</u> <ul style="list-style-type: none"><li>• More than 60 days after 2<sup>nd</sup> dose</li><li>• Not admitted to hospital</li><li>• Symptoms for 10 days</li><li>• Fully recovered</li></ul> | <u>8 cases after 1<sup>st</sup> dose</u> <ul style="list-style-type: none"><li>• 2 hospitalized</li><li>• All recovered</li></ul> | <u>5 cases after 2<sup>nd</sup> dose</u> <ul style="list-style-type: none"><li>• All after 60 days</li><li>• None admitted to hospital</li><li>• All recovered</li></ul> |

## Limitations

- Participants were from different countries with different health care systems and resources; thus conclusions may not extend to each setting
- The majority of participants were adults (81%)
- The average time between 2<sup>nd</sup> dose and participation in the survey was 112 days and therefore does not address long-term protection

## Acknowledgments

The Trisomy 21 Research Society (T21RS) COVID-19 Taskforce developed the survey, with the financial and dissemination support of Down Syndrome Affiliates in Action (DSAIA), Down Syndrome Medical Interest Group-USA (DSMIG-USA), GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society (NDSS), and the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). These and other international Down syndrome organizations are members of the T21RS COVID-19 stakeholders advisory group that provided advice to inform the design of the survey questions and interpretation of results, including the Global Down Syndrome Foundation (USA), DSA (UK), DSMIG (UK), DSMIG (USA), DSRF-UK, DSi, DSE international, Trisomie21-France, Down España, National Down Syndrome Congress (NDSC), Down Madrid, Fundació Catalana Síndrome de Down (Spain), EDSA, Royal College of Psychiatrists, CoordDown (Italy), Associazione Italiana Persone Down (AIPD; Italy), AFRT (France), Fundación Iberoamericana Down 21 (Spain), FIADOWN (Latin America), Federação Brasileira das Associações de Síndrome de Down (Brazil) and the European Down Syndrome Association. We acknowledge the contribution of DS-Connect® (The Down Syndrome Registry) which is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH for the dissemination of the T21RS survey. We also wish to thank the many families and clinicians who contributed to the survey.